Epoetin alfa biosimilar (UBI Pharma)

阿法依伯汀生物类似药 (UBI Pharma)

Report date: 2023/12/07 20:00:52

Base Information

Drug NameEpoetin alfa biosimilar (UBI Pharma)
Drug Alias NameUB-851
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnited Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesUbi Pharma Inc
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA02
Related LinksN/A